Dalcetrapib – restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease

Bibliography

• Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
   PubMed Web of Science ®Google Scholar
• Rubins HB, Davenport J, Babikian V, Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL-cholesterol. The veterans affairs hdl intervention trial (VA-HIT). Circulation 2001;103:2828-33
   PubMed Web of Science ®Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001;357:905-10
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;379:153-60
   Google Scholar
• Nissen DE, Tardif J-C, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, van Leuven SI, Burgess L, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised double-blind trial. Lancet 2007;379:153-60
   Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxglucose positron emission tomography/computed tomography. Am Heart J 2011;162:214-21
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-55
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease. Expert Opin Investig Drugs 2006;15:99-106
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Stores ES, Kasterlein JJ, Benardeau A, Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol 2009;158:1763-70
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ES, Steiner G, Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91
   PubMed Web of Science ®Google Scholar
• Stein EA, Roth EM, Rhyne JM, Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Mwangi A, Meneses-Lorente G. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010;66:775-83
   PubMed Web of Science ®Google Scholar
• A study of the effect of dalcetrapib on atherosclerotic disease in patients with coronary artery disease. Available from http://clinicaltrials.gov/ct2/show/NCT01059682?term=DALCETRAPIB&rank=2 Accessed 26 October 2011
   Google Scholar
• Kastelein JJ, Duivenvoorden R, Deanfield J, Rationale and design of dal-Vessel: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow mediated vasodilatation. Curr Med Res Opin 2011;27:141-50
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-903
   PubMed Web of Science ®Google Scholar
• Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert Opin Pharmacother 2008;9:875-8
   PubMed Web of Science ®Google Scholar
• Mullard A. Learning lessons from Pfizer's $800 million failure. Nat Rev 2011;10:163-5
   Google Scholar
• Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extended treatment beyond statins in the high-risk cardiovascular patient. Postgrad Med 2011;87:776-82
   Web of Science ®Google Scholar
• Niesor EJ, Magg C, Ogawa N, Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-54
   PubMed Web of Science ®Google Scholar
• Cao G, Beyer TP, Zhang Y, Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011;52:2169-76
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, Safety of anacetrapib in patients with or at high risk of coronary artery heart disease. N Engl J Med 2010;363:2406-15
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kasterlein JJ, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
   PubMed Web of Science ®Google Scholar